MOG (35-55): Gold-Standard Peptide for Experimental Autoimmune Encephalomyelitis Models

Executive Summary: MOG (35-55) is a synthetic peptide derived from human myelin oligodendrocyte glycoprotein, widely used to induce experimental autoimmune encephalomyelitis (EAE) in mice (APExBIO). It elicits robust T and B cell-mediated neuroinflammation, closely modeling multiple sclerosis (MS) pathology (Xu et al., 2025). The peptide triggers oxidative stress and matrix metalloproteinase-9 (MMP-9) activation in vitro, and is validated for dose-dependent disease induction in vivo. Protocols require precise solubilization and storage to ensure experimental fidelity. MOG (35-55) is central for dissecting autoimmune mechanisms and benchmarking therapeutic interventions in MS research.

Biological Rationale

Myelin oligodendrocyte glycoprotein (MOG) is a minor component of CNS myelin, belonging to the immunoglobulin superfamily. The MOG (35-55) peptide spans amino acids 35 to 55 of the human protein. Its sequence is highly immunogenic in susceptible mouse strains. EAE, induced by MOG (35-55), closely recapitulates the relapsing-remitting and chronic phases of human multiple sclerosis. The disease model is characterized by T cell-driven demyelination, neuroinflammation, and motor deficits (Xu et al., 2025). Type I interferon signaling, modulated by STAT1/STAT2, plays a crucial regulatory role in the immune response triggered by MOG (35-55) administration (Xu et al., 2025).

Mechanism of Action of MOG (35-55)

MOG (35-55) induces EAE by mimicking an autoantigenic epitope of the myelin sheath. Upon administration, typically with complete Freund's adjuvant (CFA), the peptide is taken up by antigen-presenting cells. These cells present MOG (35-55) to CD4+ T cells, driving their activation and differentiation into pathogenic Th1 and Th17 subsets. The immune response leads to CNS infiltration, demyelination, and neurological deficits. B cell responses, including the production of anti-MOG autoantibodies, further amplify disease severity. In vitro, MOG (35-55) increases NADPH oxidase activity and MMP-9 production, indicating roles in oxidative injury and extracellular matrix remodeling. The pathway involves JAK/STAT signaling, with recent findings implicating PARP7-mediated regulation of STAT1/2 stability and downstream interferon signaling (Xu et al., 2025).

Evidence & Benchmarks

• MOG (35-55) induces severe, chronic EAE in HLA-DR2-transgenic mice and other susceptible strains (Xu et al., 2025, DOI).
• Subcutaneous administration of 50–150 μg triggers dose-dependent EAE severity and weight loss in C57BL/6 mice (product sheet, APExBIO).
• In vitro, MOG (35-55) decreases protein concentration and increases NADPH oxidase and MMP-9 activity, supporting oxidative and matrix remodeling pathways (product sheet, APExBIO).
• PARP7 inhibition stabilizes STAT1/2, enhances type I interferon signaling, and attenuates EAE symptoms in MOG (35-55)-induced models (Xu et al., 2025, DOI).
• MOG (35-55) stock solutions are stable at -20°C when desiccated but degrade rapidly at room temperature or upon repeated freeze-thaw cycles (product sheet, APExBIO).

This article extends "MOG (35-55): The Gold Standard Peptide for Experimental A..." by providing granular, evidence-based workflow parameters and molecular mechanism updates, including the latest PARP7-STAT1/2 findings.

It clarifies and updates "MOG (35-55) Peptide: Unraveling Immune Mechanisms and Red..." by integrating oxidative stress and matrix remodeling data with current interferon signaling evidence.

Applications, Limits & Misconceptions

MOG (35-55) is the reference peptide for inducing EAE in preclinical MS research. Its applications include:

• Modeling relapsing-remitting and chronic MS in genetically susceptible mouse strains.
• Dissecting adaptive immune responses, including T cell and B cell epitope mapping.
• Testing immunomodulatory drugs and gene knockout/knock-in strategies.
• Studying the interplay between oxidative stress, matrix remodeling, and neuroinflammation (MOG (35-55): Beyond EAE Induction offers additional perspectives on immune pathway dissection; this article adds updated in vitro benchmarks and mechanistic clarity).

Common Pitfalls or Misconceptions

• Not all mouse strains are susceptible: BALB/c and SJL mice show variable or poor EAE induction with MOG (35-55) alone.
• Peptide solubility is buffer-dependent: MOG (35-55) is insoluble in ethanol; use sterile water (≥32.25 mg/mL) or DMSO (≥86 mg/mL) for stock solutions.
• Repeated freeze-thaw cycles degrade peptide: Always aliquot and store desiccated at -20°C to preserve activity.
• EAE does not fully recapitulate all aspects of human MS: The model mirrors neuroinflammation and demyelination but lacks certain progressive features.
• In vitro findings (e.g., NADPH oxidase activation) may not directly translate in vivo: Cellular context and immune milieu differ.

Workflow Integration & Parameters

For experimental use, dissolve MOG (35-55) in sterile water at 0.50 mg/mL, applying gentle warming and ultrasonic bath treatment to enhance solubility. The peptide is compatible with CFA for EAE induction protocols. Typical mouse dosing is 50–150 μg per injection, subcutaneously, with disease onset monitored by clinical scoring and weight tracking. Stock solutions should be aliquoted and stored desiccated at -20°C; avoid repeated freeze-thaw cycles. For in vitro assays, verify peptide solubility and buffer compatibility. Control experiments should include vehicle-only and adjuvant-only groups. For detailed troubleshooting and workflow optimization, see "MOG (35-55): The Gold-Standard Multiple Sclerosis Model P..."; this article incorporates recent molecular mechanism insights and updated solubility parameters.

Conclusion & Outlook

MOG (35-55) remains the gold-standard for inducing EAE and modeling MS in vivo. Its well-characterized immunopathogenicity, validated by numerous peer-reviewed studies and product benchmarks from APExBIO, supports its use in both mechanistic and translational neuroimmunology research. Ongoing advances in deciphering downstream signaling—such as PARP7-STAT1/2 regulation—are refining our understanding of disease modulation and therapeutic intervention opportunities (Xu et al., 2025). Proper handling and protocol adherence are essential for reproducibility and model fidelity. As molecular insights evolve, MOG (35-55) will continue to be indispensable for preclinical discovery and validation in multiple sclerosis research.